# Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)

> **NCT02332499** · PHASE2,PHASE3 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 419 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02332499
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-08-18
- **Final completion:** 2019-03-01
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332499, "Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02332499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*